LIVE

ORKA

Oruka Therapeutics, Inc.

ORKA

NASDAQ·Healthcare·Biotechnology·Mkt cap $3.5B

$85.21

▼ -8.66%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$12.10 - $97.78

P/E

-35.65

Fwd P/E

-33.53

Beta

-0.30

Div Yield

0.00%

Avg Vol

1.7M

Shares Out

37.5M

Mkt Cap

$3.5B

Price action

Price chart

Up 639.8% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

3 reasons

  • Proprietary monoclonal antibody platform technology
  • Focused pipeline targeting underserved I&I indications
  • Clinical-stage candidates with differentiated mechanisms of action
▼

Bear Case

1 risk

  • Low volatility (beta -0.3).

Growth

Revenue decline expected

Clinical trial progression of ORKA-001 and ORKA-002

Value

Deep value opportunity - significant discount to Biotech & Therapeutics peers

Momentum

Hot

+75.0% over 3m

Quality

Loss-making

Solid business

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Aug 10, 2026

“
Q2 26 RECAP

MAY 13, 2026

Reported EPS of -$0.48 vs -$0.52 consensus (+7.7% surprise).

EPS beat +7.7%

EPS surprise · last 4Q

1 of 1 beats

Q2 26

+7.7%

Next: Aug 10, 2026

Revenue trend · last 8Q

—

—

—

—

—

—

—

—

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$0

$0

$0

$0

$0

$0

$0

$0

Margins · last 8Q

No margin history available.

View full earnings history →

Wall Street consensus

9 analysts · 100% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

9

100%

Hold

0%

Sell

0%

Median Price Target

$155.50

▲ +82.5% vs $85.21

Low $85.00
Median $155.50
High $200.00

Latest: UBS · Jul 1, 2026

8 analysts covering

View full analyst page →

vs Industry

How ORKA stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.